[Optimizing basal insulin therapy in type 2 diabetes].

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes management often requires insulin therapy due to disease progression and increased life expectancy.
• Current guidelines recommend basal insulin, often with metformin, as a preferred initial injectable therapy.
• Failure to achieve glycemic targets necessitates treatment optimization.

Purpose of the Study:

• To discuss therapeutic options for type 2 diabetes patients whose glycemic control is inadequate on basal insulin.
• To evaluate the advantages and disadvantages of different treatment intensification strategies.

Main Methods:

• This is a clinical case discussion.
• Exploration of three distinct therapeutic strategies for optimizing insulin therapy.
• Consideration of adding oral agents (DPP-4 inhibitors or SGLT2 inhibitors) or GLP-1 receptor agonists.

Main Results:

• The case highlights the need for individualized treatment adjustments when basal insulin alone is insufficient.
• Discusses the potential benefits and drawbacks of switching to basal-bolus or basal-plus insulin regimens.
• Examines the role of adding oral hypoglycemic agents or injectable non-insulin therapies.

Conclusions:

• Intensifying therapy beyond basal insulin is crucial for achieving glycemic control in type 2 diabetes.
• Treatment decisions should weigh the pros and cons of insulin regimen adjustments versus adding non-insulin agents.
• Combination therapy with basal insulin and GLP-1 receptor agonists presents a viable option for further glycemic improvement.